Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.63 |
| ▸ | CA2 | P00918 | 1/20 | 0.63 |
| ▸ | CA7 | P43166 | 1/20 | 0.63 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.63 |
| ▸ | HPGD | P15428 | 2/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.60 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.60 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.60 |
| ▸ | HDAC7 | Q8WUI4 | 4/20 | 0.60 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.60 |
| ▸ | HDAC10 | Q969S8 | 4/20 | 0.60 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.60 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.60 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.60 |
| ▸ | HDAC9 | Q9UKV0 | 4/20 | 0.60 |
| ▸ | HDAC5 | Q9UQL6 | 4/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | RORC | P51449 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30805754 | 1.00 | CA1 (0.63) | CA1CA2CA7CA14HPGD | |
| SCHEMBL7761938 | 0.86 | HDAC3 (0.65) | CA1CA2CA7CA14HPGD | |
| SCHEMBL10931873 | 0.86 | POLB (0.63) | HPGDLMNAHDAC3HDAC4HDAC1 | |
| SCHEMBL26976319 | 0.84 | CA1 (0.66) | CA1CA2CA7CA14HPGD | |
| SCHEMBL11216704 | 0.84 | HPGD (0.61) | HPGDLMNAHDAC3HDAC4HDAC1 | |
| SCHEMBL29246426 | 0.83 | HDAC8 (0.70) | HPGDLMNAHDAC3HDAC4HDAC1 | |
| SCHEMBL1947846 | 0.83 | CA1 (0.59) | CA1CA2CA7CA14HPGD | |
| SCHEMBL3021548 | 0.83 | LMNA (0.86) | HPGDLMNAHDAC3HDAC4HDAC1 | |
| SCHEMBL8384204 | 0.83 | LMNA (0.59) | HPGDLMNAHDAC3HDAC4HDAC1 | |
| SCHEMBL5907668 | 0.81 | HPGD (0.67) | HPGDLMNAHDAC3HDAC4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118307431-A | Method for synthesizing beta-alkylamide from N-phenyl-3-butenamide | 南京工业大学 | 2024-07-09 | — | — | CN | disclosed |
| CN-115137672-A | Compound essential oil and glycerin body and preparation method and application thereof | 浙江万里学院 | 2022-10-04 | — | — | CN | disclosed |
| EP-2696873-B1 | PLASMODIAL SURFACE ANION CHANNEL INHIBITORS FOR THE TREATMENT OR PREVENTION OF MALARIA | US HEALTH (US) | 2022-08-03 | — | — | EP | disclosed |
| CN-114805108-A | Preparation method of chiral beta-alkyl amide compound | 南方科技大学 | 2022-07-29 | — | — | CN | disclosed |
| US-20020183313-A1 | 1,4-benzodiazepinones and their uses as CCK antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-12-05 | — | — | US | disclosed |
| US-20020002163-A1 | 1,4-benzodiazepinones and their uses as CCK antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-01-03 | — | — | US | disclosed |
| US-6291452-B1 | CHOLECYSTOKININ ANTAGONISTS. | FUJISAWA PHARMACETICAL CO., LTD. (JP) | 2001-09-18 | — | — | US | disclosed |
| US-6235730-B1 | ANTICHOLESTEROL AGENT, ANTILIPEMIC AGENT | JAPAN TOBACCO, INC. (JP) | 2001-05-22 | — | — | US | disclosed |
| EP-0970954-A1 | 3-PIPERIDYL-4-OXOQUINAZOLINE DERIVATIVES AND MEDICINCAL COMPOSITIONS CONTAINING THE SAME | JAPAN TOBACCO INC. (JP) | 2000-01-12 | — | — | EP | disclosed |
| EP-0934282-A1 | 1,4-BENZODIAZEPINONES AND THEIR USES AS CCK ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-08-11 | — | — | EP | disclosed |
| WO-1998015535-A1 | 1,4-BENZODIAZEPINONES AND THEIR USES AS CCK ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-04-16 | — | — | WO | disclosed |
| EP-0034292-B1 | PROCESS FOR THE PREPARATION OF ANTHRANILIC ACID DERIVATIVES | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1983-11-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020002163-A1 | 1,4-benzodiazepinones and their uses as CCK antagonists | CCKAR, CCKBR, GABRA4 | CA1 724/4885CA2 798/4885CA7 1911/4885 |
| US-20020183313-A1 | 1,4-benzodiazepinones and their uses as CCK antagonists | CCKAR, CCKBR, GABRA4 | CA1 724/4885CA2 798/4885CA7 1911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.